SCM
LGND icon

Snyder Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Snyder Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-241,053
Closed -$16.9M – 74
2022
Q1 		$16.9M Sell
241,053
-5,851
-2% -$425K 0.43% 68
2021
Q4 		$23.8M Buy
246,904
+43,418
+21% +$4.01M 0.57% 63
2021
Q3 		$17.7M Sell
203,486
-1,922
-0.9% -$149K 0.47% 68
2021
Q2 		$16.8M Buy
205,408
+76,366
+59% +$6.35M 0.47% 63
2021
Q1 		$12.3M Sell
129,042
-172,813
-57% -$16.3M 0.35% 68
2020
Q4 		$18.7M Buy
301,855
+24,687
+9% +$1.41M 0.61% 58
2020
Q3 		$16.5M Sell
277,168
-363
-0.1% -$24.8K 0.71% 48
2020
Q2 		$19.4M Buy
277,531
+2,913
+1% +$185K 0.88% 38
2020
Q1 		$12.5M Buy
+274,618
New +$15.6M 0.71% 47

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Snyder Capital Management's LGND Position: Q2 2022 in Review

Snyder Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 241,053 shares — an estimated $16.9M sold.

Snyder Capital Management first reported a position in LGND in Q1 2020 and held it in 9 quarters. The position peaked at $23.8M in Q4 2021. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

  • Snyder Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Snyder Capital Management sold 241,053 Ligand Pharmaceuticals shares in Q2 2022, an estimated $16.9M.
  • Snyder Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Snyder Capital Management's Ligand Pharmaceuticals position peaked at $23.8M in Q4 2021.
  • 197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on Snyder Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.